Summit Wealth Group’s NewAmsterdam Pharma NAMS Stock Holding History

Summit Wealth Group’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$730K	Buy	+30,000	New	+$829K	0.15%	57

Other funds holding NAMS

Medicxi Ventures Management St. Helier, Jersey $127M AUM 21.77% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Mizuho Markets Cayman Grand Cayman, Cayman Islands $2.12B AUM 114.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Peregrine Capital Management Minneapolis, Minnesota $2.95B AUM 28.43% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

Summit Wealth Group's NAMS Position: Q3 2026 in Review

Summit Wealth Group opened a new position in NewAmsterdam Pharma (NAMS) in Q3 2026: 30,000 shares worth $730K. The stake represents 0.15% of the portfolio and ranks #57 among its holdings.

58 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.

Summit Wealth Group held 30,000 shares of NewAmsterdam Pharma worth $730K as of Q3 2026.
NewAmsterdam Pharma was a new Summit Wealth Group position in Q3 2026.
NewAmsterdam Pharma made up 0.15% of Summit Wealth Group's portfolio in Q3 2026, its #57 holding.
58 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.

Based on Summit Wealth Group's 13F filing for Q3 2026, filed 9 Nov 2026.